Results 131 to 140 of about 1,452,849 (304)
Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy [PDF]
, 2018 BACKGROUND: The PIVOT trial examined whether patients with suppressed viral load on combination antiretroviral therapy could be safely switched long-term to ritonavir-boosted protease inhibitor (PI) monotherapy.
Dunn, DT +6 more
core +1 more source
Cysteine proteinase inhibitors: purification and gene isolation [PDF]
, 1989 Genetic engineering has produced a transgenic insect- resistant plant which produces a serine protease inhibitor (Hilder et al., 1987). More insects can be targetted if a plant can be made to produce thiol protease inhibitors.
Fones, Angela Mei Ling
core
Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation
Molecular Oncology, EarlyView.How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim +11 more
wiley +1 more source
Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer
Molecular Oncology, EarlyView.Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba +5 more
wiley +1 more source
Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy
Molecular Oncology, EarlyView.LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir +9 more
wiley +1 more source
Therapeutic outcomes of children on protease inhibitor-based antiretroviral therapy.
, 2019 Therapeutic outcomes of children on protease inhibitor-based antiretroviral therapy.
Paul Olivier Koki Ndombo (6475622) +6 more
core +1 more source
Molecular Oncology, EarlyView.This paper shows that size‐exclusion chromatography and sequential centrifugation applied to seminal plasma enrich for different populations of extracellular vesicles. This may significantly affect the detection and analysis of extracellular vesicle‐associated cancer biomarkers.
Elen Telumyan +8 more
wiley +1 more source
USP7 inhibits FOXO1 activity in chronic lymphocytic leukaemia cells enhancing cell survival
Molecular Oncology, EarlyView.CLL cells rely on BCR‐mediated signalling for survival and proliferation in part through suppression of FOXO1. FOXO1 activity is regulated by a plethora of post‐translational modifications including phosphorylation and ubiquitination. We demonstrated that dual inhibition of BCR signalling and the deubiquitinase USP7 activates FOXO1, modulating its ...
Hassan N.B. Almuhanna +8 more
wiley +1 more source
Design and synthesis of a potential inhibitor for DEN2 NS2B/NS3 serine protease / Lee Yean Kee [PDF]
, 2011 This work involves searching and designing of inhibitors for DEN2 NS2B/NS3 serine protease. It comprises three phases: modeling, synthesis and screening.
Lee, Yean Kee
core
Molecular characterization of covRS mutations in M1UK Streptococcus pyogenes
FEBS Open Bio, EarlyView.Group A Streptococcus (GAS) acquires covRS mutations driving a hypervirulent bacterial state, frequently associated with invasive disease‐like necrotizing fasciitis. We demonstrate that the newly emerged M1UK GAS lineage can also acquire these mutations.
Jarrad Pritchard +12 more
wiley +1 more source